NASDAQ
Aurinia Pharmaceuticals Inc. (AUPH) has a price/sales ratio of 7.57x as of Friday, May 22, 2026. This represents a 63.18% decrease compared to its 12-month average of 20.56x. The price-to-sales ratio evaluates a company's stock price relative to its revenue, useful for valuing companies with little or no earnings.
No price data available for this timeframe.